NEPTUNE MatchNCT04571658
NEPTUNE Match Study
At risk: Primary completion moved 12 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 14 versions: 10 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Dec 30, 2029 to Dec 30, 2030
Notable Eligibility criteria expanded, about 4 words Show 4 more changesShow less
- Secondary endpoints: details revised at 3 of 3 entries
- Site details revised at 4 of 16 sites
- Publications: details revised at 5 of 5 entries
- Study description expanded, about 4 words
- Notable Primary and study completion pushed from Jun 30, 2029 to Dec 30, 2029v11
- Notable Phase: Not specified to Not applicable
- Start date: Mar 1, 2021 to May 2, 2022
- Trial status: Enrolling by Invitation to Recruiting
- Site details revised at 16 of 16 sites
- Notable Primary and study completion dates: Jun 30, 2026 to Jun 30, 2029
- Site details revised at 1 of 16 sites
Show 4 earlier versionsHide 4 earlier versions
- Notable Primary and study completion dates: Jun 30, 2024 to Jun 30, 2026v7
- Minor Study sites: 1 to 16v5
- Notable Trial status: Not Yet Recruiting to Enrolling by Invitation
- Start date changed from estimate of Jan 31, 2021 to Mar 1, 2021
- Site contact updated
- Notable Start date: Oct 31, 2020 to Jan 31, 2021v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
Approximately 375 participants will be consented from the NEPTUNE observational study with age and demographic groups representing the patient population in the NEPTUNE study site geographical areas. NEPTUNE observational cohort eligibility includes: participants in NEPTUNE observational cohort A are of any age and have a biopsy-confirmed diagnosis of Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), or Membranous Nephropathy (MN). Participants in NEPTUNE observational cohort B have documented NS based on proteinuria, serum albumin, and/or edema with age of onset less than 19 years.
Other: Communication
Sites
16 sites in 1 country